RBC Bioscience Corporation (6848) Fair Value & Analysis
Healthcare · TW · Market cap 276M TWD
Fair value as of: Jul 21, 2026
From 22 valuation models · updated 19 days ago
Share price −6.4% over the past month.
A solid business, but screening 24% overvalued on our models.
What matters now
- Solid but not exceptional quality (58/100) and above fair value, neither a clear bargain nor a standout compounder.
- Our model range runs from 14.04 TWD (bear) to 23.62 TWD (bull), base 14.94 TWD. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 58/100 (solid quality) with high evidence: the data supports the verdict.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 21, 2026.
How to read this chart
57‑month range 10.52 TWD – 35.53 TWD · fair‑value band 14.04 TWD – 23.62 TWD · the 19.75 TWD price screens above the 14.94 TWD fair value. Dashed = 300-day average. As of Jul 21, 2026.
Analysis
RBC Bioscience Corporation (6848) currently trades at 19.75 TWD, while our model-based Fair Value estimate is 14.94 TWD, implying the stock looks roughly 24.4% overvalued today. The Quality Score stands at 58/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, RBC Bioscience Corporation generated revenue of 220M TWD at a net margin of 10.7%. Revenue grew 19.0% year over year. It earns a return on equity of 9.1%. Net debt stands at 399M TWD. Fundamentals as of Jul 21, 2026
Our scenario range runs from 14.04 TWD (bear case) to 23.62 TWD (bull case); at 19.75 TWD, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 8% below its 52-week high and 38% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -24%, 6848 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 22 models by family
Widest divergence: Multiples (25.69 TWD) versus Growth DCF (6.92 TWD). Highest evidence: Growth DCF (80).
Notify me when 6848 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 21, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 55 · Market factors (momentum, volatility) 68
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
RBC Bioscience Corporation manufactures and sells reagents and devices for life science and molecular diagnosis Taiwan. It offers MagCore Plus II Automated Nucleic Acid Extractor, a robotic bench-top workstation for nucleic acid purification; MagCore Super Automated Nucleic Acid Extractor, an automated workstation for nucleic acid extraction; and MagCore® …
Full company description
RBC Bioscience Corporation manufactures and sells reagents and devices for life science and molecular diagnosis Taiwan. It offers MagCore Plus II Automated Nucleic Acid Extractor, a robotic bench-top workstation for nucleic acid purification; MagCore Super Automated Nucleic Acid Extractor, an automated workstation for nucleic acid extraction; and MagCore® EDA Automatic Extraction and Smart PCR Setup, an instrument for nucleic acid extraction and PCR setup pre-treatment. The company also provides NGS, genomic DNA, viral nucleic acids, and total RNA kits. RBC Bioscience Corporation was founded in 1995 and is based in New Taipei City, Taiwan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2020 – FY2024 · reported fiscal years
RBC Bioscience Corporation reported revenue of 205M TWD in FY2024 versus 575M TWD in FY2020, a compound −22.7%/yr. Reported net income was 21.6M TWD in FY2024, compounding −37.6%/yr from FY2020.
6848 screens 24% overvalued. Compare with Vertex Pharmaceuticals Incorporated →
Peer Group
Biotechnology · 601 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 21, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $486.03 | $278.78 | -43% |
| Regeneron Pharmaceuticals, Inc REGN | $664.45 | $594.40 | -11% |
| Samsung Biologics Co 207940 | 1,368,000 KRW | 1,091,384 KRW | -20% |
| Celltrion, Inc 068270 | 175,800 KRW | 76,325 KRW | -57% |
| WuXi Biologics (Cayman) Inc 2269 | HK$39.54 | HK$30.42 | -23% |
| Innovent Biologics, Inc 1801 | HK$86.70 | HK$19.66 | -77% |
| Sino Biopharmaceutical Limited 1177 | HK$5.26 | HK$3.36 | -36% |
| ALTEOGEN Inc 196170 | 276,500 KRW | 44,444 KRW | -84% |
| RemeGen Co 688331 | ¥134.02 | ¥26.99 | -80% |
| Biocon Limited BIOCON | ₹440.70 | ₹57.36 | -87% |
Compare RBC Bioscience Corporation with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is RBC Bioscience Corporation (6848) overvalued or undervalued?
What is the fair value of 6848?
What is the quality score of 6848?
What is the revenue of RBC Bioscience Corporation (6848)?
What is the net profit margin of 6848?
Does RBC Bioscience Corporation pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track RBC Bioscience Corporation and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.